COV-AD study sheds further light on reduced COVID-19 vaccine effectiveness for people with immunodeficiency, UK Covid Vaccine Research Hub

New findings from the COV-AD study team have shown that people with immunodeficiency are considerably less likely to generate antibodies to fight COVID-19 following vaccination. Immunodeficiency can arise from a wide range of conditions, and sometimes from the treatments people receive for an illness. Primary immunodeficiency occurs as a result of genetic factors, while secondary immunodeficiency is usually caused by an illness such as blood cancer. People with immunodeficiency are at risk of severe and recurrent infection, and often don ' t respond well to vaccination. The study team recruited 320 people with immunodeficiency (defined as being on immunoglobulin therapy or having an IgG of less than 4g per litre and receiving antibiotic prophylaxis). Their responses to two doses of COVID-19 vaccine were compared with those of a group of 205 controls without antibody deficiency.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news